



Office of The Commissioner,  
Food & Drugs Administration M.S.  
Bandra – Kurla Complex,  
Bandra (E),  
Mumbai – 400 051  
Date :-26 Mar 2021

## CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.

(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/PD/100630/2021/11/35612**

On the basis of the inspection carried out on **14/12/2020** , **15/12/2020** and **05/02/2021** ,we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **BADRIVISHAL CHEMICALS AND PHARMACEUTICALS**  
Address : **GAT NO. 29, VILLAGE - JAMWADE (INDURI), POST - SUDUMBRE, TAL - MAVAL PUNE 412109 MAHARASHTRA STATE, INDIA**
2. Licence No. : **PD130 In Form 25, PD78 In Form 28**

Table 1

| Sr.No. | Dosage Form(s)                                  | Categor(ies)   | Activity(ies)   |
|--------|---|--|---|
| 1      | Active Pharmaceutical Ingredients ( Bulk Drugs) | General ( Other than Cephalosporins, Penicillin, Cytotoxic, Hormones ) | Synthesis, Purification, Packing, Labelling, Quality Control, Quality Assurance |

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 25 Mar 2024 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority :  
Food & Drug Administration, M.S.  
Bandra-kurla Complex,  
Bandra (E), Mumbai – 400 051  
Maharashtra, INDIA.  
Tel: +91-22-26592363/64  
Fax: +91-22-26591959  
1DAB11210063020210326  
BADRIVISHAL CHEMICALS AND  
PHARMACEUTICALS - NEW-WHO-GMP/CERT  
/PD/100630/2021/11/35612

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**

**Food & Drug Administration, M.S.**

**Bandra (E), Mumbai.**

**Maharashtra State, India**

**Date:26 Mar 2021**



### Explanatory notes

1. This certificate which is in the format recommended by WHO, certifies the status of the site listed in point 1 of the certificate.
2. The certification number should be traceable within the regulatory authority issuing the certificate.
3. Where the regulatory authority issues a licence for the site, this number should be specified record "not applicable" in cases where there is no legal framework for the issuing of a licence.
4. Table 1  
List the dosage forms, starting materials, categories and activities. Examples are given below.

#### Example -1



| Pharmaceutical Product (s) <sup>1</sup> | Category (ies) | Activity (ies)                             |
|---|----------------|--|
| Dosage form (s)                         |                |  |
| Tablets                                 | Cytotoxic      | Packaging                                  |
|   | Hormone        | Production, Packaging, Quality control.    |
| Injectables                             | Penicillin     | Repackaging & Labelling.                   |
|   | Cefalosporin   | Aseptic preparation, Packaging, Labelling. |

#### Example - 2.

| Pharmaceutical Product (s) <sup>1</sup> | Category (ies) | Activity (ies)                               |
|---|----------------|--|
| Starting material (s) <sup>2</sup>      |                |  |
| Paracetamol                             | Analgesic      | Synthesis, Purification, Packing, Labelling. |

Use, whenever available. International Nonproprietary Names (INNs) or otherwise national nonproprietary names.

5. The certificate remains valid until the specified date. The certificate becomes invalid if the activities and/or categories certified are changed or if the site is no longer considered to be in compliance with GMP.
6. The requirements for good practices the manufacture and quality control of drugs referred to in the certificate are those included in Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials. Good manufacturing practices and inspection. Volume 2, 1999. World Health Organization, Geneva and subsequent updates.



**LIST OF PRODUCT APPROVED UNDER WHO GMP<sup>1</sup>**

**No. of certificate** : NEW-WHO-GMP/CERT/PD/100630/2021/11 VALID UP TO :25 Mar 2024  
/35612

**Name of Manufacturing Firm** : BADRIVISHAL CHEMICALS AND  
PHARMACEUTICALS  
GAT NO. 29, VILLAGE - JAMBWADE (INDURI),  
POST - SUDUMBRE, TAL - MAVAL PUNE 412109  
MAHARASHTRA STATE, INDIA

**Drug License No** : PD130 In Form 25, PD78  
In Form 28

| Sr.No. | Name of the Product     | Composition |
|--------|-------------------------|-------------|
| 1      | DOCUSATE SODIUM BP      |             |
| 2      | DOCUSATE SODIUM IP      |             |
| 3      | DOCUSATE SODIUM PH.EUR. |             |
| 4      | DOCUSATE SODIUM USP     |             |

Address of certifying authority :  
Food & Drug Administration, M.S.  
Bandra-kurla Complex,  
Bandra (E), Mumbai – 400 051.  
Maharashtra,INDIA.  
Tel: +91-22-26592363/64  
Fax: +91-22-26591959  
1DAB11210063020210326  
BADRIVISHAL CHEMICALS AND  
PHARMACEUTICALS - NEW-WHO-GMP/CERT  
/PD/100630/2021/11/35612

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**  
**Food & Drug Administration, M.S.**

**Bandra (E), Mumbai.**

**Maharashtra State, India**

**Date:26 Mar 2021**

